BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Newly diagnosed patients with chronic-phase chronic myeloid leukemia (CP-CML) are treated with tyrosine kinase inhibitors (TKI) including imatinib, dasatinib, nilotinib, or bosutinib which specifically block BCR-ABL activity [1].